Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Adult patient with sickle cell anemia (SS homozygous, SC heterozygous compound Sbetathal heterozygous)~Exclusion Criteria:~* Heterozygous sickle cell anemia~* Active infection~* Hypersensitivity known or suspected to Prevenar 13® or to Pneumo 23® or to any of the excipients included in the formulation or in the administration system~* Coagulation abnormality indicating against an intramuscular injection (Platelets \<50 000 or TP\<50%)~* Current chemotherapy or radiotherapy, except for using Siklos®/Hydrea® in the context of sickle cell anemia~* Vaccination whatever in the last 2 months before the protocol vaccination, except influenza vaccination (within 30 days)~* Vaccination whatever, provided in the first 2 months following the protocol vaccinations, except influenza vaccination (within the first month following the protocol vaccinations))~* History of pneumococcal vaccination with Pneumo 23® in the previous year~* End-stage renal failure(dialyzed patient, clearance\<10ml/mn)~* HIV infection at baseline~* Pregnancy or breastfeeding (A dosage of betaHCG will be conducted for women in childbearing age),contraception recommendation the first 8 weeks of the test for women in childbearing age~* Participation in a clinical research protocol using a drug within the month prior to inclusion.~* No medical assurance~* Adults under tutelage

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCV vaccine following by the PSV vaccine (Type: EXPERIMENTAL): Group 1: patients will receive a first boost with 13-valent pneumococcal conjugate vaccine (PCV) (one dose at W0) and then one administration of the PSV vaccines (one dose at W4).
- vaccine Pneumo 23 (Type: ACTIVE_COMPARATOR): Group 2: patients will receive a single administration of 23-valent pneumococcal polysaccharide vaccine (PSV) (one dose at W4)

Based on this trial design, predict the completion outcome and termination type (if applicable).